The Helmholtz Sino-German Research Laboratory for Cancer, Department of Pathology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
FEBS Lett. 2014 Mar 18;588(6):981-9. doi: 10.1016/j.febslet.2014.01.058. Epub 2014 Feb 14.
Esophageal squamous cell carcinomas (ESCCs) are highly invasive and have poor prognoses. We investigated the role of PTPLAD2, a protein tyrosine phosphatase-like A domain (PTPLAD) family member, in ESCC carcinogenesis. Survival analysis was performed using patient data. ESCC tissue samples lost PTPLAD2 heterozygosity and had decreased PTPLAD2 expression. Low PTPLAD2 expression and high p-STAT3 correlated with poor prognosis. Overexpression of PTPLAD2 in ESCC cells reduced STAT3 phosphorylation, decreased FoxM1, inhibited proliferation and decreased in mouse xenograft tumor formation. Therefore, PTPLAD2 is a potential tumor suppressor and prognostic indicator that reduces STAT3 phosphorylation. PTPLAD2 is a possible clinical target for ESCC treatment.
食管鳞状细胞癌 (ESCC) 具有高度侵袭性和预后不良。我们研究了蛋白酪氨酸磷酸酶样 A 结构域 (PTPLAD) 家族成员 PTPLAD2 在 ESCC 发生中的作用。使用患者数据进行生存分析。ESCC 组织样本失去了 PTPLAD2 杂合性，并且 PTPLAD2 表达降低。低表达 PTPLAD2 和高表达 p-STAT3 与预后不良相关。在 ESCC 细胞中过表达 PTPLAD2 可降低 STAT3 磷酸化，降低 FoxM1，抑制增殖并减少小鼠异种移植肿瘤的形成。因此，PTPLAD2 是一种潜在的肿瘤抑制因子和预后指标，可降低 STAT3 磷酸化。PTPLAD2 可能是 ESCC 治疗的临床靶点。
